CVS Returns Lilly Obesity Drug to Formularies After Removal
CVS Health has reversed course and returned Eli Lilly's obesity medication to its pharmacy benefit formularies after previously removing it. The decision affects coverage for weight loss treatments across CVS's prescription drug plans. The timing and specific reasons for the reversal were not detailed in the report. The formulary change impacts pharmacy benefit management decisions for health plans that rely on CVS Caremark's formulary recommendations, including some Medicaid managed care organizations that contract with CVS.
Formulary changes by major PBMs like CVS Caremark directly affect drug coverage decisions and pharmacy spend for Medicaid managed care plans, particularly as obesity treatment coverage expands under some state Medicaid programs.
Pharmacy · Managed Care
You might also like